{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:05:03Z","timestamp":1790661903850,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1053\/j.ajkd.2021.08.016","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T05:17:06Z","timestamp":1633151826000},"page":"737-745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward"],"prefix":"10.1053","volume":"79","author":[{"given":"Justin M.","family":"Belcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Vela","family":"Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Simonetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Juncos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithin","family":"Karakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani M.","family":"Wadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Regner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra K.","family":"Nadim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Q.","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Allegretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2021.08.016_bib1","doi-asserted-by":"crossref","first-page":"108139","DOI":"10.1155\/2015\/108139","article-title":"Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study","volume":"2015","author":"Allegretti","year":"2015","journal-title":"Int J Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.26980","article-title":"Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury","volume":"60","author":"Belcher","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2021.08.016_bib3","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/hep.22605","article-title":"Acute kidney injury in cirrhosis","volume":"48","author":"Garcia-Tsao","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2021.08.016_bib4","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jhep.2011.03.012","article-title":"Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice","volume":"55","author":"Salerno","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.08.016_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12664-020-01086-z","article-title":"Short-term mortality in patients with cirrhosis of the liver and acute kidney injury: a prospective observational study","volume":"39","author":"Kumar","year":"2020","journal-title":"Indian J Gastroenterol"},{"key":"10.1053\/j.ajkd.2021.08.016_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"New in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document","volume":"71","author":"Angeli","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.08.016_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"key":"10.1053\/j.ajkd.2021.08.016_bib8","first-page":"1","article-title":"In\u00a0vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2","volume":"10","author":"Jamil","year":"2017","journal-title":"J\u00a0Exp Pharmacol"},{"key":"10.1053\/j.ajkd.2021.08.016_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1053\/j.ajkd.2021.08.016_bib10","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/liv.14703","article-title":"Terlipressin has stood the test of time: clinical overview in 2020 and future perspectives","volume":"40","author":"Kulkarni","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1053\/j.ajkd.2021.08.016_bib11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/BF02088218","article-title":"Hepatorenal syndrome: long-term treatment with terlipressin as a bridge to liver transplantation","volume":"41","author":"Ganne-Carri\u00e9","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.ajkd.2021.08.016_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.08.016_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jceh.2020.09.005","article-title":"INASL-ISN joint position statements on managements of patients with simultaneous liver and kidney disease","volume":"11","author":"Arora","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"Suppl 2","key":"10.1053\/j.ajkd.2021.08.016_bib15","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.dld.2021.03.035","article-title":"Position paper on liver and kidney disease from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology","volume":"53","author":"Morelli","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2021.08.016_bib16","first-page":"CD013103","article-title":"Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis","volume":"9","author":"Best","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1053\/j.ajkd.2021.08.016_bib17","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2021.08.016_bib18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A\u00a0randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2021.08.016_bib19","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2021.08.016_bib20","first-page":"67","article-title":"Verified hepatorenal syndrome reversal as a robust multi-compartment primary end point: the CONFIRM study design","volume":"11","author":"Jamil","year":"2019","journal-title":"J\u00a0Clin Trials"},{"issue":"9","key":"10.1053\/j.ajkd.2021.08.016_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11894-020-00783-1","article-title":"Cirrhotic cardiomyopathy","volume":"22","author":"Yoon","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1053\/j.ajkd.2021.08.016_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.14309\/ajg.0000000000000462","article-title":"Impaired cardiac reserve on dobutamine stress echocardiography predicts the development of hepatorenal syndrome","volume":"115","author":"Koshy","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.ajkd.2021.08.016_bib23","doi-asserted-by":"crossref","unstructured":"Terres AZ, Balbinot RS, Muscope ALF, et\u00a0al. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol. Published online April 8, 2021. https:\/\/doi.org\/10.1016\/j.gastrohep.2021.02.007","DOI":"10.1016\/j.gastrohep.2021.02.007"},{"issue":"8","key":"10.1053\/j.ajkd.2021.08.016_bib24","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/liv.13375","article-title":"Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion","volume":"37","author":"Shasthry","year":"2017","journal-title":"Liver Int"},{"issue":"9","key":"10.1053\/j.ajkd.2021.08.016_bib25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa2022166","article-title":"A\u00a0randomized trial of albumin infusions in hospitalized patients with cirrhosis","volume":"384","author":"China","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.08.016_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2019.03.021","article-title":"Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis","volume":"157","author":"Fernandez","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1053\/j.ajkd.2021.08.016_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000501299","article-title":"Point-of-care echocardiography unveils misclassification of acute kidney injury as hepatorenal syndrome","volume":"50","author":"Velez","year":"2019","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.08.016_bib28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.kint.2017.11.032","article-title":"Point-of-care ultrasound in the practice of nephrology","volume":"93","author":"Niyyar","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2021.08.016_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5811\/westjem.2016.12.32489","article-title":"Inferior vena cava measurement with ultrasound: that is the best view and best mode?","volume":"18","author":"Finnerty","year":"2017","journal-title":"West J Emerg Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.08.016_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1553-2712.2010.00952.x","article-title":"The interrater reliability of inferior vena cava ultrasound by bedside clinician sonographers in emergency department patients","volume":"18","author":"Field","year":"2011","journal-title":"Acad Emerg Med"},{"issue":"4","key":"10.1053\/j.ajkd.2021.08.016_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000517363","article-title":"Albumin infusion in patients with cirrhosis: time for POCUS-enhanced physical examination","volume":"11","author":"Koratala","year":"2021","journal-title":"Cardiorenal Med"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","author":"Boyer","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib33","first-page":"274","article-title":"Hepatorenal syndrome: response to terlipressin and albumin and its determinants","volume":"32","author":"Sarwar","year":"2016","journal-title":"Pak J Med Sci"},{"issue":"7","key":"10.1053\/j.ajkd.2021.08.016_bib34","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/apt.15836","article-title":"Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome","volume":"52","author":"Moore","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2021.08.016_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s10620-019-05858-2","article-title":"Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002-2018: a systematic review and meta-analysis","volume":"65","author":"Thomson","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1053\/j.ajkd.2021.08.016_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MCG.0000000000000913","article-title":"Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis","volume":"52","author":"Nanda","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"5","key":"10.1053\/j.ajkd.2021.08.016_bib38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials","volume":"25","author":"Sagi","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"11","key":"10.1053\/j.ajkd.2021.08.016_bib39","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17474124.2017.1356223","article-title":"Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis","volume":"11","author":"Zheng","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"16","key":"10.1053\/j.ajkd.2021.08.016_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010431","article-title":"Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1053\/j.ajkd.2021.08.016_bib41","first-page":"CD005162","article-title":"Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome","volume":"6","author":"Allegretti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1053\/j.ajkd.2021.08.016_bib42","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/lt.25834","article-title":"Role of terlipressin and albumin for hepatorenal syndrome in liver transplantation","volume":"26","author":"Sharma","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1053\/j.ajkd.2021.08.016_bib43","doi-asserted-by":"crossref","unstructured":"Skagen C, Einstein M, Lucey MR, et\u00a0al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 200;43(7):680-685. https:\/\/doi.org\/10.1097\/MCG.0b013e318188947c","DOI":"10.1097\/MCG.0b013e318188947c"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2021.08.016_bib45","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.ajkd.2011.07.017","article-title":"Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials","volume":"58","author":"Velez","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2021.08.016_bib46","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/MEG.0000000000000988","article-title":"Terlipressin is superior to midodrine\/octreotide for hepatorenal syndrome type 1","volume":"29","author":"Kalambokis","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1053\/j.ajkd.2021.08.016_bib47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/gastro\/goz043","article-title":"Pharmacological treatment of hepatorenal syndrome: a network meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"Gastroenterol Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2021.08.016_bib49","first-page":"CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome","volume":"9","author":"Israelsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.ajkd.2021.08.016_bib51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-28032016000200014","article-title":"Terlipressin versus noradrenaline for hepatorenal syndrome. Economic evaluation under the perspective of the Brazilian Public Health Service","volume":"53","author":"Mattos","year":"2016","journal-title":"Arq Gastroenterol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.08.016_bib52","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2021.08.016_bib53","doi-asserted-by":"crossref","first-page":"675948","DOI":"10.3389\/fphar.2021.675948","article-title":"Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial","volume":"12","author":"El-Desoki Mahmoud","year":"2021","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2021.08.016_bib54","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1007\/s10620-020-06370-8","article-title":"Terlipressin for type 1 hepatorenal syndrome","volume":"65","author":"Terbah","year":"2020","journal-title":"Dig Dis Sci"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621008908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638621008908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:44:46Z","timestamp":1759463086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638621008908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0272638621008908"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.08.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.","name":"copyright","label":"Copyright"}]}}